|
2024
|
Invention
|
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compo... |
|
|
Invention
|
Anti-ror antibody constructs.
Anti-ROR antibody constructs, pharmaceutical compositions comprisi... |
|
|
Invention
|
Activatable tyrosine-protein kinase membrane receptor (ror) antibody-drug conjugates and uses the... |
|
|
Invention
|
Interleukin-13 receptor subunit alpha-2 binding agents and uses thereof. e.ge.g, antibodies, incl... |
|
|
Invention
|
Activatable ror binding agents and uses thereof. The present disclosure provides activatable ROR ... |
|
|
Invention
|
Tyrosine-protein kinase membrane receptor 1 (ror1) antibody-drug conjugates and uses thereof. The... |
|
|
Invention
|
Interleukin-13 receptor subunit alpha-2 antibody-drug conjugates and uses thereof. The present di... |
|
|
Invention
|
Fused pyrazole derivatives as usp1 inhibitors. The present disclosure provides fused pyrazole der... |
|
|
Invention
|
Method of treating cancer and bone cancer pain.
This invention is directed to the treatment of c... |
|
|
Invention
|
Liquid dosage forms to treat cancer.
This invention relates to a liquid pharmaceutical compositi... |
|
|
Invention
|
Crystalline forms and salt forms of a kinase inhibitor.
The present invention relates to crystal... |
|
|
Invention
|
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane... |
|
|
Invention
|
Amhrii antibody-drug conjugates and uses thereof. The present disclosure provides AMHRII antibody... |
|
|
Invention
|
Dll3 antibody-drug conjugates and uses thereof. The present disclosure provides DLL3 antibody-dru... |
|
|
Invention
|
Malate salt of n-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropan... |
|
|
Invention
|
Nkg2a binding agents and uses thereof. The present disclosure provides NKG2A binding agents (e.g,... |
|
|
Invention
|
Method of treating cancer.
This invention is directed to the treatment of cancer, particularly c... |
|
2023
|
Invention
|
Compounds that inhibit pkmyt1. Disclosed herein are compounds according to Formula (I). Compounds... |
|
|
Invention
|
Compounds that inhibit pkmyt1. Disclosed herein are compounds according to Formula I. (I). Compou... |
|
|
Invention
|
C-met modulator pharmaceutical compositions.
Pharmaceutical compositions and unit dosage forms c... |
|
|
Invention
|
C]pyridine compounds and derivatives as usp1 inhibitors. Hcc]pyridine compounds of formula (I), w... |
|
|
Invention
|
Triple negative breast cancer treatment method.
Disclosed is a method of treating triple negativ... |
|
|
Invention
|
Tissue factor antibody-drug conjugates and uses thereof. The present disclosure provides anti-tis... |
|
|
Invention
|
Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cycl... |
|
|
Invention
|
Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n’-(4-f... |
|
|
Invention
|
Agents that bind to nkg2a and pd-l1 and uses thereof. e.g.e.g., multispecific antibodies such as ... |
|
|
Invention
|
Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophe... |
|
|
Invention
|
Compounds for the treatment of kinase-dependent disorders. Disclosed herein are compounds of Form... |
|
|
Invention
|
Heterocyclic adenosine receptor antagonists.
Heterocyclic compounds useful as antagonists of ade... |
|
|
Invention
|
Cancer therapy using a combination of a cdk7 inhibitor with an oral serd. The present invention p... |
|
|
Invention
|
5t4 antibody-drug conjugates and uses thereof. The present disclosure provides 5T4 antibody-drug ... |
|
|
Invention
|
5t4 binding agents and uses thereof. The present disclosure provides 5T4 binding agents (e.g., an... |
|
|
Invention
|
Compounds for the treatment of kinase-dependent disorders.
Disclosed herein are compounds of For... |
|
|
Invention
|
Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates. Provided herei... |
|
|
Invention
|
Method of treating cancer. This invention is directed to the treatment of cancer, particularly ca... |
|
|
Invention
|
Multispecific binding agents and uses thereof. The present disclosure provides multispecific bind... |
|
|
Invention
|
Pharmaceutical compositions comprising anti-tissue factor antibody-drug conjugates. Provided here... |
|
2022
|
Invention
|
Crystalline forms and salt forms of a kinase inhibitor. The present invention relates to crystall... |
|
|
Invention
|
Crystalline forms and salt forms of a kinase inhibitor. in vivoin vivo activity of a protein kinase. |
|
|
Invention
|
Compounds for the treatment of kinase-dependent disorders.
Disclosed herein are compounds of for... |
|
|
Invention
|
Liquid dosage forms to treat cancer. This invention relates to a liquid pharmaceutical compositio... |
|
|
Invention
|
Pyridone compounds and methods of use.
The present disclosure relates generally to compounds and... |
|
2021
|
Invention
|
Pharmaceutical compositions of a kinase inhibitor.
The present invention relates to pharmaceutic... |
|
|
Invention
|
Method of treating cancer.
This invention is directed to the treatment of cancer, particularly s... |
|
|
Invention
|
Multispecific binding agents and uses thereof.
The present disclosure provides multispecific bin... |
|
|
Invention
|
Cd47 binding agents and uses thereof.
The present disclosure provides CD47 binding agents (e.g.,... |
|
|
Invention
|
Pd-l1 binding agents and uses thereof.
The present disclosure provides PD-L1 binding agents (e.g... |
|
|
Invention
|
Combinations for the treatment of cancer.
The present invention relates to combinations comprisi... |
|
2020
|
Invention
|
Amh-competitive antagonist antibody.
The present invention relates to a competitive antagonist a... |
|
2019
|
G/S
|
Online information services, namely, providing scientific research information related to oncolog... |
|
2018
|
G/S
|
Pharmaceutical preparations for the treatment of cancer, pain, infection, inflammation, hormone d... |
|
2017
|
G/S
|
Business administration of patient reimbursement programs in order to assist patients in obtainin... |
|
|
G/S
|
Pharmaceutical research and development services |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer,
pain, infection, inflammation, hormone ... |
|
2016
|
G/S
|
Pharmaceutical preparations for the treatment of cancer, pain, hormone disorders in the field of ... |
|
2014
|
G/S
|
Pharmaceutical preparations for the treatment of cancer, pain, disorders of the endocrine system,... |
|
|
G/S
|
Pharmaceutical preparations; chemical, analytical and diagnostic reagents for in vivo use; analge... |
|
2012
|
G/S
|
Pharmaceutical preparations for the treatment of cancer, pain, infection, inflammation, disorders... |
|
|
G/S
|
Chemicals and biochemicals for use in science, research and for laboratory use; chemical, analyti... |
|
2009
|
G/S
|
Pharmaceutical research and development services. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer. Pharmaceutical research and development ... |
|
2008
|
G/S
|
pharmaceutical research and development services |
|
2002
|
G/S
|
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and ... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer. |
|
2001
|
G/S
|
pharmaceutical preparations for the treatment of cancer |
|
1999
|
G/S
|
Books, pamphlets and brochures featuring information on research and development in the field of ... |
